Costedoat-Chalumeau Nathalie, Dunogué Bertrand, Leroux Gaëlle, Morel Nathalie, Jallouli Moez, Le Guern Véronique, Piette Jean-Charles, Brézin Antoine P, Melles Ronald B, Marmor Michael F
Université René Descartes Paris V, Paris, France.
Centre de Référence Maladies Auto-Immunes et Systémiques Rares, Service de Médecine Interne Pôle Médecine, Hôpital Cochin, AP-HP, 27 rue du Faubourg Saint Jacques, 75679, Paris Cedex 14, France.
Clin Rev Allergy Immunol. 2015 Dec;49(3):317-26. doi: 10.1007/s12016-015-8469-8.
Hydroxychloroquine (HCQ) and chloroquine have been used for more than 50 years to treat systemic lupus erythematosus (SLE) and other rheumatic diseases. In general, these drugs are well tolerated and rarely need to be discontinued because of an adverse systemic reaction. However, both medications can be irreversibly toxic to the retina. A new study indicates that toxicity is not as rare as once believed, but depends critically on daily dosage and duration of use, as well as other risk factors. With attention to dosage and other factors, and with proper screening for early signs of toxicity, HCQ can be prescribed with relative safety even over long periods of time.
羟氯喹(HCQ)和氯喹已被用于治疗系统性红斑狼疮(SLE)及其他风湿性疾病50多年。总体而言,这些药物耐受性良好,很少因全身性不良反应而停药。然而,这两种药物都可能对视网膜产生不可逆毒性。一项新研究表明,毒性并不像曾经认为的那样罕见,而是严重取决于每日剂量、使用时长以及其他风险因素。注意剂量和其他因素,并对毒性早期迹象进行适当筛查,即使长期使用,羟氯喹也可相对安全地开具处方。